SEARCH

SEARCH BY CITATION

Keywords:

  • inflammation;
  • nerve growth factor;
  • overactive bladder;
  • pathophysiology

Abstract

Objective

To investigate the serum nerve growth factor (NGF) and urinary NGF levels in patients with overactive bladder syndrome (OAB) refractory to antimuscarinic therapy.

Materials and Methods

Thirty-four patients with OAB (17 OAB-dry and 17 OAB-wet) and 31 normal subjects were enrolled. The patients were diagnosed to have OAB based on symptoms of urgency with/without urgency incontinence and 3-day voiding diary. All OAB patients had been treated with previous antimuscarinic therapy for at least 3 months but had failed. Serum and urine were collected at baseline and after solifenacin treatment for 3 months. The serum NGF and urinary NGF levels were compared between OAB-dry and OAB-wet and between baseline and after solifenacin treatment.

Results

Serum NGF levels were significantly elevated in OAB (median and interquartile range, 7.367 pg/ml, 0–57.66) compared to the controls (0.0728 pg/ml, 0–0.234, P < 0.001). Urinary NGF/Cr levels were significantly elevated in patients with OAB (0.685 pg/mg, 0.08–1.94) compared to the controls (0.005 pg/mg, 0–0.0275, P < 0.001). Serum NGF levels were significantly correlated with urinary NGF (P = 0.002) and NGF/Cr levels (P < 0.001) in OAB patients. There was no significant difference of serum NGF levels between OAB-dry and OAB-wet. The serum and urinary NGF levels remained unchanged (P = 0.504 and 0.414, respectively) in OAB patients after solifenacin therapy. The serum NGF levels were highly correlated between baseline and after solifenacin treatment (R2 = 0.83, P < 0.001).

Conclusions

Increased serum and urinary NGF levels in patients with OAB refractory to antimuscarinic treatment suggest these bladder disorders might be caused by chronic inflammation. Neurourol. Urodynam. Neurourol. Urodynam. 30: 1525–1529, 2011. © 2011 Wiley Periodicals, Inc.